Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Pavel Kapysh / Shutterstock Arcimoto (NASDAQ: FUV ) stock is on a wild ride today after the electric vehicle (EV) company revealed plans for a strategic restructuring. According to a filing with the U...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today is a big day for Intercept Pharmaceuticals (NASDAQ: ICPT ). The company just announced the clinical-trial results of Intercept’s treatment for NASH cirrhosis. Unfortunately, those results didn’t ...
Investors have had a hard time navigating the current stock market environment, and Friday didn't seem likely to bring any obvious answers to resolve the many uncertainties plaguing Wall Street right now. Futures on the Nasdaq Composite (NASDAQINDEX: ^IXIC) were all over the map in ...
Intercept Pharmaceuticals ( NASDAQ: ICPT ) stock fell ~18% on Sept. 30 after the company said obeticholic acid (OCA) failed to show improvement in fibrosis with no worsening of a liver disease, thus not meeting the main goal of a phase 3 trial. The study, d...
MORRISTOWN, N.J., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that REVERSE, a Phase 3 stud...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: rafapress / Shutterstock.com Clovis Oncology (NASDAQ: CLVS ) stock is getting a boost on Wednesday as investors react to news of it reaching a two-year clinical supply agreement . That agreement was s...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: asharkyu / Shutterstock.com Freyr Battery (NYSE: FREY ) stock is a hot topic among traders on Wednesday after Morgan Stanley weighed in on the electric vehicle (EV) company. That comes from Morgan Stan...
Intercept Pharmaceuticals ( NASDAQ: ICPT ) has reduced its outstanding debt by 54% to $336.3M as the company seeks to improve its capital structure. In addition, the company has decreased its annual cash interest expense by 58% to $9.8M on an annual basis. As a result,...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Postmodern Studio / Shutterstock Intercept Pharmaceuticals (NASDAQ: ICPT ) stock is on the move Wednesday after giving investors an update on how it improved its financials . A press release from the ...
Outstanding debt reduced by 54% or $388.9 million and annual cash interest expense reduced by 58% or $13.6 million Company well-positioned to drive continued growth in PBC, progress NASH program, expand and advance pipeline MORRISTOWN, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE)...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...